Dr. Katie Larson Ode has been named director of the Clinical Core component of the University of Iowa’s Center for Gene Therapy of Cystic Fibrosis. The NIH grant funding for this project was just renewed. Her core will support maintenance and growth of a Cystic Fibrosis biobank which will obtain/provide clinical samples from/to researchers in cystic fibrosis for translational projects. Congratulations to Dr. Larson Ode on your excellent work.
It has been a productive fall for Dr. Larson Ode, who has published 5 review articles focused on various endocrine complications of cystic fibrosis. You can find summaries of these works at the following links: one – two – three – four – five. Dr. Larson Ode is a leading expert in the clinical care and clinical research involving persons with cystic fibrosis who have developed diabetes and other endocrine complications. She sees children and adult patients in the cystic fibrosis clinic to help them manage these conditions. On the research side, she coordinates a variety of clinical studies here at Iowa and also at other academic medical centers across the country to better understand these complications. She is also serving as a career and research mentor to several junior endocrinology faculty across the country to further their expertise and research in this important area. Kudos Dr. Larson Ode on your accomplishments!
There is a strong need to train endocrinologist to help provide expert care for the endocrine complications experienced by patients with cystic fibrosis. For this reason, the Cystic Fibrosis Foundation has established a program to identify national leaders in this area who can help mentor other endocrinologists. We are proud of Dr. Katie Larson Ode, who has been named one of the selected mentors to help train the future leaders in cystic fibrosis endocrinology. This honor includes grant funds to support her time in these efforts.
Dr. Larson Ode is the principal investigator and leader of an ongoing multicenter research study aimed at better understanding cystic fibrosis related diabetes. The study is funded by the Cystic Fibrosis Foundation (https://www.cff.org/). The name of the study is the “EnVision CF Multicenter Study of Glucose Tolerance in Cystic Fibrosis”, and will be funded at least through August 2021. As the leader of the study, Dr. Larson Ode coordinates studies at the University of Iowa, the University of Minnesota, University of Colorado, and Washington University in St Louis.
We are proud of Dr. Katie Larson Ode, who is giving an invited lecture today at the European Cystic Fibrosis Society annual Conference in Liverpool, UK. The title of her lecture as “CFRD (cystic fibrosis related diabetes) in the age of correctors”. Dr. Larson Ode is an internationally recognized expert in the care of patients with CFRD. Patients with cystic fibrosis are now being treated with powerful medications that directly restore function of the defective protein that causes their disease. These medications dramatically improve lung function, but their impact on cystic fibrosis related diabetes is less clear. In her talk, Dr. Larson Ode will review available data and discuss ongoing uncertainties.